Protara Therapeutics Inc - Asset Resilience Ratio

Latest as of June 2026: 71.22%

Protara Therapeutics Inc (TARA) has an Asset Resilience Ratio of 71.22% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Protara Therapeutics Inc (TARA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$125.42 Million
Cash + Short-term Investments

Total Assets

$176.09 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Protara Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Protara Therapeutics Inc.

Liquid Assets Composition Over Time

This chart breaks down Protara Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore TARA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $125.42 Million 71.22%
Total Liquid Assets $125.42 Million 71.22%

Asset Resilience Insights

  • Very High Liquidity: Protara Therapeutics Inc maintains exceptional liquid asset reserves at 71.22% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Protara Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Protara Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Vaxcyte Inc
NASDAQ:PCVX
Biotechnology 41.54%
Enliven Therapeutics Inc.
NASDAQ:ELVN
Biotechnology 83.46%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.12%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%

Annual Asset Resilience Ratio for Protara Therapeutics Inc (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Protara Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 50.56% $105.90 Million $209.47 Million +46.43pp
2024-12-31 4.13% $7.49 Million $181.45 Million -28.79pp
2023-12-31 32.92% $25.99 Million $78.95 Million -20.25pp
2022-12-31 53.18% $60.24 Million $113.29 Million +21.02pp
2021-12-31 32.16% $55.51 Million $172.60 Million --
2020-12-31 0.00% $0.00 $203.16 Million --
2019-12-31 0.00% $0.00 $6.97 Million --
2018-12-31 10.61% $2.50 Million $23.52 Million -37.07pp
2017-12-31 47.68% $20.97 Million $43.98 Million +36.37pp
2016-12-31 11.32% $4.92 Million $43.52 Million -26.04pp
2015-12-31 37.36% $25.23 Million $67.54 Million +19.96pp
2014-12-31 17.40% $14.76 Million $84.80 Million -24.29pp
2013-12-31 41.69% $2.36 Million $5.66 Million -23.86pp
2012-12-31 65.55% $5.10 Million $7.78 Million --
pp = percentage points

About Protara Therapeutics Inc

NASDAQ:TARA USA Biotechnology
Market Cap
$197.97 Million
Market Cap Rank
#16661 Global
#3952 in USA
Share Price
$3.35
Change (1 day)
-5.37%
52-Week Range
$3.35 - $7.56
All Time High
$664.40
About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more